inovio.com (INO) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Inovio Pharmaceuticals (INO) possesses market power due to its unique method of delivering DNA instructions into cells via the Cellectra and SynCon systems. Financial quote visualization on GURU.Markets shows that the EV/EBITDA ratio is 0.00. The business model is easily scalable through low-cost drug replication and patent licensing. Meanwhile, the company retains key immunologists by shifting toward targeted specialist hiring.

INO (Inovio Pharmaceuticals Inc) EV/EBITDA Multiple history from 11/23/2025 to 11/12/2026

Analytical breakdowns for Inovio Pharmaceuticals

- current price and projected stock value:

Stock Price Inovio Pharmaceuticals Inc|INO - Analyst Median Target

- market capitalization details:

Market Value Inovio Pharma|INO - Value Adjusted for Debt and Cash

- book value of equity indicators:

Accounting Value per Share Inovio|INO - Book Capitalization|Market Value to Book Value Ratio inovio.com|INO - Company Total Asset Base

- debt and solvency information:

- net income and valuation multiples indicators:

INO - Net Financial Result|Expected Profit Inovio Pharmaceuticals|INO - Market Cap to Earnings|Projected Price to Earnings Inovio Pharmaceuticals|INO - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inovio Pharma|INO - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Inovio|INO - Earnings per share for the trailing year|Quarterly EPS earnings growth inovio.com|INO - Earnings growth in current year|Net earnings per share growth forecast for next year Inovio Pharmaceuticals

Fundamental company valuation:INO (Inovio Pharmaceuticals Inc)

The success of Inovio Pharmaceuticals (INO) depends on the commercialization of the Cellectra platform and regulatory approval of new vaccines. By analyzing the EV/EBITDA multiple trend, an investor observes the ratio of the total enterprise value, including debt, to operating profit. This metric determines the payback period of assets without accounting for the tax shield and debt load. The stability of this indicator confirms the fundamental resilience of Inovio Pharmaceuticals (INO) in the current cycle.

Competitor analysis

EV/EBITDA Multiple GILD (Gilead Sciences Inc)|Total Company Value to Operating Income Before Depreciation Ratio Cidara (CDTX)|NVAX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CVAC (curevac.com)|VALN (Valneva) - Enterprise Value to EBITDA Ratio|Vir Biotechnology Inc (VIR) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SIGA Corp|Emergent Bio (EBS) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple AVIR|Total Company Value to Operating Income Before Depreciation Ratio invivyd.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Enanta Pharmaceuticals, Inc. ENTA|HLVX: Enterprise Value to Operating Income Before Depreciation|KLRS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Dyadic International|NNVC (nanoviricides.com) - Enterprise Value to EBITDA Ratio|TLPH (talphera.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|COCP (Cocrystal Pharma) - EV/EBITDA Multiple|Traws Therapeutics (TRAW) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Dogwood Therapeutics, Inc. (DWTX)|QLGN - Company Value to EBITDA|AlloVir - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VBIV|VIRI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VXRT